Medical Care and Payment for Diabetes in China: Enormous Threat and Great Opportunity
Open Access
- 26 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e39513
Abstract
The Diabetes Impact Study followed up a large national population-based screening study to estimate the use of and expenditures for medical care caused by diabetes in China and to ascertain the use and cost of essential basic medicines and care. In 2009–10, the study team interviewed 1482 adults with diabetes and 1553 adults with glucose tolerance in the normal range from population-based random samples at 12 sites in China. The response rate was 67%. After adjusting for age, sex, and urban/rural location, people with diabetes received 1.93 times more days of inpatient treatment, 2.40 times more outpatient visits, and 3.35 times more medications than people with normal glucose tolerance (all p<0.05). Adjusted expenditures for medical care were 3.38 times higher among people with diabetes than among people with normal glucose tolerance (p<0.01, unadjusted 3.97). Persons who were diagnosed with ≥10 years prior to the survey paid 3.75 times as much for medical care as those with ≤5 years of diagnosed diabetes. Among persons with diabetes, 45.2% took medication to control blood sugar, 21.1% took an antihypertensive medicine, 22.4% took daily aspirin, and 1.8% took a statin. Over the three months before the interview, 46.1% of persons with diabetes recalled seeing a doctor, 48.9% recalled a blood pressure measurement, and 54.5% recalled a blood sugar test. Over the year preceding the interview, 32.1% recalled a retinal screening and 17.9% recalled a foot examination. In China, health care use and costs were dramatically higher for people with diabetes than for people with normal glucose tolerance and, in relative terms, much higher than in industrialized countries. Low-cost generic medicines that would reduce diabetes expenditures were not fully used.Keywords
This publication has 28 references indexed in Scilit:
- Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic ReviewDiabetes Care, 2010
- Prevalence of Diabetes among Men and Women in ChinaNew England Journal of Medicine, 2010
- Global healthcare expenditure on diabetes for 2010 and 2030Diabetes Research and Clinical Practice, 2010
- Type 2 diabetes mellitus in China: a preventable economic burden.2009
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trialThe Lancet, 2009
- Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 DiabetesNew England Journal of Medicine, 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costsThe Lancet, 2007
- The burden and costs of chronic diseases in low-income and middle-income countriesThe Lancet, 2007